Pancreatic Cancer Research

ResearcherAzienda Ospedaliera Carlo PomaActive in the last 2 years

Fausto Petrelli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9639-4486; OpenAlex author ID A5058439511. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 4 papers · 2018: none · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 4 papers

Papers 20

  1. Targeting RAS in pancreatic cancer. Co-author DOI 10.1002/cncr.70640↗
  2. Early onset pancreatic Cancer: epidemiology, molecular features, and clinical outcomes. Co-author DOI 10.1016/j.ctrv.2026.103170↗
  3. Rethinking Optimal Therapy for Operable Pancreatic Cancer in the CASSANDRA Era. Co-author DOI 10.1200/jco-25-02920↗
  4. Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses. Last author DOI 10.3390/cancers18091344↗
  5. Comparative Efficacy of 21 Treatment Strategies for Resectable Pancreatic Cancer: A Network Meta-Analysis. Co-author DOI 10.3390/cancers16183203↗
  6. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. Co-author DOI 10.1007/s12029-023-00923-6↗
  7. Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis. Co-author DOI 10.1186/s12876-023-02853-w↗
  8. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. Last author DOI 10.1016/j.radonc.2021.09.001↗
  9. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Co-author DOI 10.3390/cancers13174396↗
  10. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. Last author DOI 10.21037/jgo.2018.12.08↗
  11. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and … Last author DOI 10.3390/cancers11040484↗
  12. Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/cancers11040550↗
  13. Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality? Last author DOI 10.3390/cancers11081095↗
  14. Borderline resectable pancreatic cancer: More than an anatomical concept. Co-author DOI 10.1016/j.dld.2016.11.010↗
  15. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.ejca.2017.05.025↗
  16. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. Co-author DOI 10.1016/j.hpb.2017.07.005↗
  17. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Co-author DOI 10.1016/j.ijrobp.2016.10.030↗
  18. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. Co-author DOI 10.1016/s1499-3872(15)60344-7↗
  19. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Co-author DOI 10.1097/mpa.0000000000000314↗
  20. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis. Co-author DOI 10.1016/j.dld.2014.01.001↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lorenzo Dottorini · 5 shared papers, 2024–2026 · strength 1.93
  2. Michele Ghidini · 12 shared papers, 2017–2026 · strength 1.89
  3. Gianluca Tomasello · 12 shared papers, 2017–2026 · strength 1.77
  4. Alberto Zaniboni · 3 shared papers, 2019–2026 · strength 0.89
  5. Sandro Barni · 8 shared papers, 2014–2019 · strength 0.58
  6. Shelize Sadrudin Khakoo · 3 shared papers, 2019–2023 · strength 0.41
  7. Gianpaolo Balzano · 1 shared paper, 2026 · strength 0.30
  8. Sara Cherri · 1 shared paper, 2026 · strength 0.29
  9. Ester Oneda · 1 shared paper, 2026 · strength 0.29
  10. Michele Reni · 2 shared papers, 2017–2023 · strength 0.27
  11. Stefano Cascinu · 2 shared papers, 2017–2023 · strength 0.27
  12. Angelica Petrillo · 2 shared papers, 2019–2021 · strength 0.23
  13. Umberto Peretti · 1 shared paper, 2023 · strength 0.19
  14. Marina Macchini · 1 shared paper, 2023 · strength 0.19
  15. Giulia Orsi · 1 shared paper, 2023 · strength 0.19
  16. Roberto Labianca · 2 shared papers, 2017 · strength 0.15
  17. Antonio Costanzo · 1 shared paper, 2019 · strength 0.10
  18. Tiziana Comito · 1 shared paper, 2017 · strength 0.08
  19. Marta Scorsetti · 1 shared paper, 2017 · strength 0.08
  20. Federico Nichetti · 1 shared paper, 2019 · strength 0.08
  21. Sara Pusceddu · 1 shared paper, 2019 · strength 0.08
  22. Monica Niger · 1 shared paper, 2019 · strength 0.08
  23. Massimo Falconi · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.